CUSTOMER PORTAL
For leaders in pharmaceutical and life sciences organizations, third-party risk is no longer a discrete program; it’s a persistent condition of doing business. Innovation depends on complex ecosystems of CROs, CMOs, technology providers, logistics partners, data processors, and research collaborators spread across geographies and regulatory regimes. At the same time, expectations from regulators, investors, and boards continue to intensify.
The challenge isn’t simply that risk exists. It’s that risk evolves faster than the structures designed to manage it, while regulations change in ways that demand constant recalibration.
What follows are three realities C-level leaders in pharmaceutical and life sciences must be prepared to manage as risk and regulation continue to shift.
Third-party risk no longer fits neatly into silos. A single vendor relationship can simultaneously introduce cybersecurity exposure, data privacy concerns, GxP compliance risk, ESG implications, and operational dependency. A breach at a technology provider can quickly become a regulatory issue under GDPR or HIPAA, a disclosure issue under SEC cyber rules, and a patient trust issue, all at once.
At the executive level, this convergence raises a critical question: who owns the full picture?
This challenge is not theoretical. In a recent KPMG study focused on life sciences organizations, more than two-thirds of respondents said third-party risk management is undervalued despite its critical importance, and 51% acknowledged they lack sufficient internal capability to manage third-party risk effectively.
Most concerning for executives, 76% reported experiencing supply-chain disruption, financial loss, or reputational damage as a direct result of third-party incidents. These findings underscore a hard reality for the C-suite: when accountability for third-party risk is fragmented, consequences surface not as abstract risk metrics but as material business impact.
While C-level leaders set the enterprise risk appetite and strategic priorities, execution lives across multiple functions, including Procurement managing onboarding, InfoSec assessing cyber controls, Quality overseeing GxP obligations, Legal interpreting contractual risk, and ERM attempting to aggregate it all into a coherent view. VPs translate strategy into programs, directors manage workflows, and managers chase assessments, evidence, and follow-ups.
Without a unified approach to risk domains and data, accountability fragments. Leaders are left reconciling partial views of risk rather than making informed decisions based on a single source of truth. Purpose-built TPRM platforms quietly solve this problem by normalizing risk data across domains and enabling executives to see how interconnected risks accumulate and where intervention truly matters.
In pharmaceutical and life sciences, regulatory change is a constant, not an exception. FDA and EMA expectations evolve. Data privacy regulations such as GDPR continue to mature. Cybersecurity frameworks like NIST and ISO 27001 raise the bar. Emerging AI governance requirements add new layers of scrutiny. Meanwhile, supply chain resilience and third-party transparency are increasingly in scope for regulators and boards alike.
From the C-suite perspective, compliance is not about checking boxes; it is about proving control in an environment where the rules keep moving.
This pressure cascades downward. Program leaders must update policies and methodologies. Directors must adapt processes and assessments. Managers must operationalize new requirements across thousands of third parties, often with limited resources and static tools. When systems are rigid, regulatory change becomes disruptive rather than manageable.
Adaptive TPRM technology enables organizations to respond without reinventing their programs. Configurable risk domains, flexible workflows, and intelligent automation allow regulatory requirements to be incorporated into existing structures, preserving momentum while maintaining compliance. For executives, this translates into confidence that the organization can absorb regulatory change without operational shock.
Perhaps the most underestimated challenge in TPRM is organizational alignment. Strategic goals set at the executive level, including resilience, compliance, and growth, must translate into measurable program objectives, efficient operations, and consistent execution. When alignment breaks down, risk programs become reactive, inconsistent, and difficult to defend under scrutiny.
Executives experience this misalignment indirectly: delayed escalations, conflicting risk ratings, inconsistent reporting, and last-minute remediation efforts triggered by audits or incidents. The issue is rarely intent; it is infrastructure. When teams operate across disconnected tools and manual processes, alignment becomes aspirational rather than operational.
Intelligent, enterprise-grade TPRM platforms act as connective tissue, linking strategy to execution. They provide shared context across roles and functions, enable standardized yet flexible processes, and surface insights that allow leaders to intervene early rather than react late. Alignment, in this sense, becomes a built-in capability rather than a management burden.
As risk evolves and regulations change, pharmaceutical and life sciences organizations need more than point solutions or incremental fixes. They need an intelligence-first approach to third-party risk, one that recognizes the complexity of the ecosystem and the realities of executive decision-making.
Aravo was built for this world. Its Intelligence First™ enterprise platform combines extensible data modeling, native AI, and configurable risk domains to support the full spectrum of third-party risk, today and as it evolves tomorrow. With premium support models to choose from, organizations gain not just technology, but a partner aligned to the demands of highly regulated industries.
For executives navigating an ever-changing risk landscape, the goal is not perfection; it is preparedness. And preparedness starts with seeing risk clearly, managing it intelligently, and aligning the entire organization around what matters most.
With global trials, critical partners under scrutiny, and regulators closing in, can you see every third-party risk in time to protect patients, keep supply flowing, and stay audit-ready?
Speak with an Aravo expert today and learn how executive alignment and adaptive TPRM approaches help protect patients, data, and supply chains while staying audit ready.
Share with Your Friends: